Stoke Therapeutics, Inc.
STOK Healthcare Biotechnology
Stoke Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $184.4 million, up 404.5% from fiscal 2024. In the quarter to June 2026, revenue fell 32.5%, EPS fell 132.5% and free cash flow fell 129.0%, each against the same quarter a year earlier.
Follow STOK
Stoke Therapeutics, Inc. (STOK) EV/Sales
As of 16 October 2026, Stoke Therapeutics, Inc. (STOK) trades at a EV/Sales of 47.2×. Over the past ten years it has ranged from −7.3× (September 2023) to 80.5× (June 2024); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.6× | (16.53%) |
| FY2024 | 10.4× | 61.25% |
| FY2023 | 6.4× | (35.71%) |
| FY2022 | 10.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 67.7× | 26.99% |
| Mar 2026 | 53.3× | 516.28% |
| Dec 2025 | 8.6× | 57.51% |
| Sep 2025 | 5.5× | 164.77% |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ZBIO Zenas BioPharma, Inc. compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| KRSA Korsana Biosciences, Inc. compare | 8.8× |
| NTLA Intellia Therapeutics, Inc. compare | 18.3× |
| OCUL Ocular Therapeutix, Inc. compare | 19.6× |
| QURE uniQure N.V. compare | 36.8× |
| STOK Stoke Therapeutics, Inc. | 47.2× |
| ABSI Absci Corporation compare | 704× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)